{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:23:20Z","timestamp":1788927800268,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Extrapyramidal symptoms affect an average of 37%, with a maximum prevalence of 71.4%, among individuals on antipsychotics. About one in five patients experiences Parkinsonism, and more than one in ten experiences akathisia. These symptoms can significantly increase relapse rates, elevate healthcare costs (approximately $27,408), and contribute to stigmatization. In Tigray, where antipsychotic use is rising, data on Extrapyramidal symptoms are limited. This study aimed to fill this research gap to better patient care and management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The aim of this study was to determine the prevalence of Extrapyramidal symptoms associated with antipsychotic medications. Additionally, it sought to identify factors contributing to these side effects among patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study was conducted across five public hospitals in the Tigray region, utilizing a comprehensive approach that included face-to-face interviews, direct observations, card reviews, and physical examinations. A total of 834 participants were selected through a multistage sampling technique to ensure representativeness, using the Extra Pyramidal Symptom Rating Scale (ESRS) for standardized evaluation. Data collected were analyzed using SPSS version 27.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result<\/jats:title>\n                    <jats:p>\n                      The study findings showed that the prevalence rates of Parkinsonism, Akathisia, Dystonia, and Tardive Dyskinesia were\n                      <jats:bold>9.9%<\/jats:bold>\n                      ,\n                      <jats:bold>6.9%<\/jats:bold>\n                      ,\n                      <jats:bold>5.0%<\/jats:bold>\n                      ,\n                      <jats:bold>and 2.4%<\/jats:bold>\n                      , respectively. The multivariate analysis revealed several common risk factors associated with these extrapyramidal symptoms. Both Parkinsonism and Akathisia were significantly associated with various factors, including the type of antipsychotic medication, illness relapse, comorbid medical conditions, anticholinergic medication, perceived stigma, and current khat use. Additionally, Parkinsonism was associated with the type of mental illness. Dystonia was also associated with marital status, anticholinergic medication, perceived stigma, and tobacco use. Lastly, Tardive Dyskinesia was associated with educational status and medication adherence.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and recommendations<\/jats:title>\n                    <jats:p>Although Extrapyramidal symptoms were reported at lower rates than in previous studies, psychiatry professionals should routinely screen for EPS and tailor treatment to patient-specific factors. Efforts to reduce stigma around these side effects are also essential to improve patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12888-025-07645-y","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T11:36:21Z","timestamp":1764070581000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prevalence and associated factors of antipsychotic-induced extrapyramidal symptoms in the Tigray region"],"prefix":"10.1186","volume":"25","author":[{"given":"Etsay Hailu","family":"Gebremariam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tesfaye Derbie","family":"Begashaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Light","family":"Tsegay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gebreslassie Gebreegziabhier","family":"Kindeya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraha Gosh","family":"Weldemariam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Welu Abadi","family":"Gebru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haftom Desta","family":"Kahsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagos","family":"Tsegabrhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"issue":"11","key":"7645_CR1","first-page":"1111","volume":"9","author":"A Shah","year":"2019","unstructured":"Shah A, Verma R, Yadav P, Patel J. Drug utilization study of antipsychotic drugs in the psychiatry outpatient department of a tertiary care hospital. Natl J Physiol Pharm Pharmacol. 2019;9(11):1111.","journal-title":"Natl J Physiol Pharm Pharmacol"},{"issue":"1","key":"7645_CR2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1080\/0964704X.2012.664847","volume":"22","author":"J Moncrieff","year":"2013","unstructured":"Moncrieff J. Magic bullets for mental disorders: the emergence of the concept of an antipsychotic drug. J Hist Neurosci. 2013;22(1):30\u201346.","journal-title":"J Hist Neurosci"},{"issue":"1","key":"7645_CR3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.22270\/jddt.v10i1.3865","volume":"10","author":"R Bangwal","year":"2020","unstructured":"Bangwal R, Bisht S, Saklani S, Garg S, Dhayani M. Psychotic disorders, definition, sign and symptoms, antipsychotic drugs, mechanism of action, pharmacokinetics & pharmacodynamics with side effects & adverse drug reactions: updated systematic review Article. J Drug Deliv Ther. 2020;10(1):163\u201372.","journal-title":"J Drug Deliv Ther"},{"issue":"10","key":"7645_CR4","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1176\/appi.ajp.20240738","volume":"181","author":"S Leucht","year":"2024","unstructured":"Leucht S, Priller J, Davis JM. Antipsychotic drugs: a concise review of history, classification, indications, mechanism, efficacy, side effects, dosing, and clinical application. Am J Psychiatry. 2024;181(10):865\u201378.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"7645_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12991-021-00348-0","volume":"20","author":"M Bahta","year":"2021","unstructured":"Bahta M, Ogbaghebriel A, Russom M, Tesfamariam EH, Berhe T. Impact of adverse reactions to first-generation antipsychotics on treatment adherence in outpatients with schizophrenia: a cross-sectional study. Ann Gen Psychiatry. 2021;20(1):27.","journal-title":"Ann Gen Psychiatry"},{"key":"7645_CR6","doi-asserted-by":"crossref","unstructured":"Ohi K, Muto Y, Sugiyama S, Shioiri T. Safety and efficacy in randomized controlled trials of second-generation antipsychotics versus placebo for cognitive impairments in schizophrenia: a meta-analysis. J Clin Psychopharmacol [Internet]. 2022 [cited 2025 May 14];42(2):227\u20139. Available from: https:\/\/journals.lww.com\/psychopharmacology\/fulltext\/2022\/03000\/safety_and_efficacy_in_randomized_controlled.24.aspx.","DOI":"10.1097\/JCP.0000000000001232"},{"key":"7645_CR7","doi-asserted-by":"crossref","unstructured":"Sakhamuri V, Valicherla SV, Kona SV, Besabathini HG. Risperidone induced extrapyramidal side effects: a rare case report. Indian J Pharm Pract. 2021;14(3).","DOI":"10.5530\/ijopp.14.3.41"},{"key":"7645_CR8","doi-asserted-by":"publisher","unstructured":"Siafis S, Wu H, Wang D, Burschinski A, Nomura N, Takeuchi H, et al. Systematic review antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis. Available from: https:\/\/doi.org\/10.1038\/s41380-023-02203-y.","DOI":"10.1038\/s41380-023-02203-y"},{"key":"7645_CR9","first-page":"1","volume":"17","author":"MO Nwokike","year":"2022","unstructured":"Nwokike MO, Ghasi SI, Ogbonna AO, Ezenwaeze MN, Ezinwa AC. Extrapyramidal symptoms and novel antipsychotic drugs. Int Neuropsychiatr Dis J. 2022;17:1\u20137.","journal-title":"Int Neuropsychiatr Dis J"},{"issue":"4","key":"7645_CR10","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1017\/S1092852922000992","volume":"28","author":"SN Caroff","year":"2023","unstructured":"Caroff SN. A new era in the diagnosis and treatment of tardive dyskinesia. CNS Spectr. 2023;28(4):401\u201315.","journal-title":"CNS Spectr"},{"issue":"1","key":"7645_CR11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1080\/13696998.2021.2019501","volume":"25","author":"A Kadakia","year":"2022","unstructured":"Kadakia A, Brady BL, Dembek C, Williams GR, Kent JM. The incidence and economic burden of extrapyramidal symptoms in patients with schizophrenia treated with second generation antipsychotics in a medicaid population. J Med Econ. 2022;25(1):87\u201398.","journal-title":"J Med Econ"},{"issue":"3","key":"7645_CR12","doi-asserted-by":"publisher","first-page":"46498","DOI":"10.4088\/JCP.22m14694","volume":"84","author":"R Jain","year":"2023","unstructured":"Jain R, Ayyagari R, Goldschmidt D, Zhou M, Finkbeiner S, Leo S. Impact of tardive dyskinesia on physical, psychological, social, and professional domains of patient lives: a survey of patients in the united States. J Clin Psychiatry. 2023;84(3):46498.","journal-title":"J Clin Psychiatry"},{"key":"7645_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1745017902117010001","volume":"17","author":"D Abu-Naser","year":"2021","unstructured":"Abu-Naser D, Gharaibeh S, Al Meslamani AZ, Alefan Q, Abunaser R. Assessment of extrapyramidal symptoms associated with psychotropics Pharmacological treatments, and associated risk factors. Clin Pract Epidemiol Ment Heal CP EMH. 2021;17:1.","journal-title":"Clin Pract Epidemiol Ment Heal CP EMH"},{"issue":"9","key":"7645_CR14","doi-asserted-by":"publisher","first-page":"e0257129","DOI":"10.1371\/journal.pone.0257129","volume":"16","author":"T Ali","year":"2021","unstructured":"Ali T, Sisay M, Tariku M, Mekuria AN, Desalew A. Antipsychotic-induced extrapyramidal side effects: A systematic review and meta-analysis of observational studies. PLoS ONE. 2021;16(9):e0257129.","journal-title":"PLoS ONE"},{"issue":"2","key":"7645_CR15","first-page":"225","volume":"59","author":"FB Shettima","year":"2023","unstructured":"Shettima FB, Sheikh TL, Wakil MA, Abdulaziz M, Rabebbe IB, O Abdulmalik J. Prevalence and correlates of extrapyramidal side effects among patients with schizophrenia spectrum disorders on typical and atypical antipsychotics. Arch Psychiatry Res Int J Psychiatry Relat Sci. 2023;59(2):225\u201340.","journal-title":"Arch Psychiatry Res Int J Psychiatry Relat Sci"},{"key":"7645_CR16","unstructured":"Prevalence. and correlates of extrapyramidal side effects among patients with schizophrenia spectrum disorders on typical and atypical antipsychotics. [Internet]. [cited 2025 May 15]. Available from: https:\/\/psycnet.apa.org\/record\/2024-39781-006."},{"issue":"2","key":"7645_CR17","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/hup.2305","volume":"28","author":"LK Hansen","year":"2013","unstructured":"Hansen LK, Nausheen B, Hart D, Kingdon D. Movement disorders in patients with schizophrenia and a history of substance abuse. Hum Psychopharmacol Clin Exp. 2013;28(2):192\u20137.","journal-title":"Hum Psychopharmacol Clin Exp"},{"key":"7645_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12889-019-7664-6","volume":"19","author":"S Han","year":"2019","unstructured":"Han S, Kim S, Kim H, Shin H-W, Na K-S, Suh HS. Prevalence and incidence of parkinson\u2019s disease and drug-induced parkinsonism in Korea. BMC Public Health. 2019;19:1\u20139.","journal-title":"BMC Public Health"},{"issue":"4","key":"7645_CR19","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/j.1600-0447.1993.tb03366.x","volume":"87","author":"J Gerlach","year":"1993","unstructured":"Gerlach J, Korsgaard S, Clemmesen P, Lauersen AL, Magelund G, Noring U, et al. The St. Hans rating scale for extrapyramidal syndromes: reliability and validity. Acta Psychiatr Scand. 1993;87(4):244\u201352.","journal-title":"Acta Psychiatr Scand"},{"key":"7645_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-244X-9-16","volume":"9","author":"I Van Rossum","year":"2009","unstructured":"Van Rossum I, Tenback D, van Os J. Bipolar disorder and dopamine dysfunction: an indirect approach focusing on tardive movement syndromes in a naturalistic setting. BMC Psychiatry. 2009;9:1\u20139.","journal-title":"BMC Psychiatry"},{"issue":"5","key":"7645_CR21","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1097\/JCP.0b013e3181f14098","volume":"30","author":"D Novick","year":"2010","unstructured":"Novick D, Haro JM, Bertsch J, Haddad PM. Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study. J Clin Psychopharmacol. 2010;30(5):531\u201340.","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"7645_CR22","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1017\/S1461145712001277","volume":"16","author":"J-P Zhang","year":"2013","unstructured":"Zhang J-P, Gallego JA, Robinson DG, Malhotra AK, Kane JM, Correll CU. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2013;16(6):1205\u201318.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"5","key":"7645_CR23","doi-asserted-by":"publisher","first-page":"76","DOI":"10.11648\/j.ajpn.20140205.12","volume":"2","author":"H Taye","year":"2014","unstructured":"Taye H, Awoke T, Ebrahim J. Antipsychotic medication induced movement disorders: the case of Amanuel specialized mental hospital, addis Ababa, Ethiopia. Am J Psychiatry Neurosci. 2014;2(5):76\u201382.","journal-title":"Am J Psychiatry Neurosci"},{"issue":"1","key":"7645_CR24","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1176\/appi.ajp.161.1.160","volume":"161","author":"S Janno","year":"2004","unstructured":"Janno S, Holi M, Tuisku K, Wahlbeck K. Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients. Am J Psychiatry. 2004;161(1):160\u20133.","journal-title":"Am J Psychiatry"},{"key":"7645_CR25","doi-asserted-by":"publisher","unstructured":"Id TA, Sisay M, Tariku M, Nigussie Mekuria A, Desalewid A. Antipsychotic-induced extrapyramidal side effects: a systematic review and meta-analysis of observational studies. 2021. Available from: https:\/\/doi.org\/10.1371\/journal.pone.0257129.","DOI":"10.1371\/journal.pone.0257129"},{"issue":"11","key":"7645_CR26","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1517\/14656566.2011.626769","volume":"13","author":"L Citrome","year":"2012","unstructured":"Citrome L. A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia. Expert Opin Pharmacother. 2012;13(11):1545\u201373.","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"7645_CR27","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/WNF.0000000000000040","volume":"37","author":"M-J Lee","year":"2014","unstructured":"Lee M-J, Lin P-Y, Chang Y-Y, Chong M-Y, Lee Y. Antipsychotics-induced tardive syndrome: a retrospective epidemiological study. Clin Neuropharmacol. 2014;37(4):111\u20135.","journal-title":"Clin Neuropharmacol"},{"issue":"9","key":"7645_CR28","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.parkreldis.2009.02.015","volume":"15","author":"CL Go","year":"2009","unstructured":"Go CL, Rosales RL, Caraos RJ, Fernandez HH. The current prevalence and factors associated with tardive dyskinesia among Filipino schizophrenic patients. Parkinsonism Relat Disord. 2009;15(9):655\u20139.","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"7645_CR29","doi-asserted-by":"publisher","first-page":"488","DOI":"10.9758\/cpn.22.1000","volume":"21","author":"P-C Chou","year":"2023","unstructured":"Chou P-C, Lee Y, Chang Y-Y, Lin P-Y, Wang L-J. The outcome of antipsychotics-induced tardive syndromes: a ten-year follow-up study. Clin Psychopharmacol Neurosci. 2023;21(3):488.","journal-title":"Clin Psychopharmacol Neurosci"},{"issue":"3","key":"7645_CR30","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/YCO.0b013e32832a16da","volume":"22","author":"R Kumar","year":"2009","unstructured":"Kumar R, Sachdev PS. Akathisia and second-generation antipsychotic drugs. Curr Opin Psychiatry. 2009;22(3):293\u20139.","journal-title":"Curr Opin Psychiatry"},{"issue":"4","key":"7645_CR31","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.euroneuro.2019.02.003","volume":"29","author":"I Pacchiarotti","year":"2019","unstructured":"Pacchiarotti I, Tiihonen J, Kotzalidis GD, Verdolini N, Murru A, Goikolea JM, et al. Long-acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: a systematic review. Eur Neuropsychopharmacol. 2019;29(4):457\u201370.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"5","key":"7645_CR32","first-page":"FC24","volume":"11","author":"A Shah","year":"2017","unstructured":"Shah A, Yadav PP, Chaudhari M, Vataliya A, Kantharia ND, Mehta R. A prospective study of adverse drug reactions in patients with bipolar disorder in psychiatry outpatient department of a tertiary care hospital. J Clin Diagn Res JCDR. 2017;11(5):FC24.","journal-title":"J Clin Diagn Res JCDR"},{"issue":"14","key":"7645_CR33","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1001\/jama.2023.18588","volume":"330","author":"AA Nierenberg","year":"2023","unstructured":"Nierenberg AA, Agustini B, K\u00f6hler-Forsberg O, Cusin C, Katz D, Sylvia LG, et al. Diagnosis and treatment of bipolar disorder: a review. JAMA. 2023;330(14):1370\u201380.","journal-title":"JAMA"},{"key":"7645_CR34","doi-asserted-by":"crossref","unstructured":"Nakaki T. Drugs that affect autonomic functions or the extrapyramidal system. In: Side effects of drugs annual. Elsevier; 2017. p. 133\u201344.","DOI":"10.1016\/bs.seda.2017.06.024"},{"issue":"13","key":"7645_CR35","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1002\/mds.23227","volume":"25","author":"S Zhornitsky","year":"2010","unstructured":"Zhornitsky S, Stip E, Pampoulova T, Rizkallah E, Lipp O, Bentaleb LA, et al. Extrapyramidal symptoms in substance abusers with and without schizophrenia and in nonabusing patients with schizophrenia. Mov Disord. 2010;25(13):2188\u201394.","journal-title":"Mov Disord"},{"issue":"suppl 3","key":"7645_CR36","first-page":"16","volume":"61","author":"WM Glazer","year":"2000","unstructured":"Glazer WM. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry. 2000;61(suppl 3):16\u201321.","journal-title":"J Clin Psychiatry"},{"issue":"16","key":"7645_CR37","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1001\/archinte.165.16.1882","volume":"165","author":"PA Rochon","year":"2005","unstructured":"Rochon PA, Stukel TA, Sykora K, Gill S, Garfinkel S, Anderson GM, et al. Atypical antipsychotics and parkinsonism. Arch Intern Med. 2005;165(16):1882\u20138.","journal-title":"Arch Intern Med"},{"key":"7645_CR38","doi-asserted-by":"crossref","unstructured":"Zwick J, Appleseth H, Arndt S. Stigma: how it affects the substance use disorder patient. Substance abuse treatment, prevention, and policy. Springer; 2020;15:1\u20134.","DOI":"10.1186\/s13011-020-00288-0"},{"key":"7645_CR39","doi-asserted-by":"publisher","first-page":"110795","DOI":"10.1016\/j.pnpbp.2023.110795","volume":"126","author":"DD Kim","year":"2023","unstructured":"Kim DD, Procyshyn RM, Jones AA, Lee LHN, Panenka WJ, Stubbs JL, et al. Movement disorders associated with substance use in adults living in precarious housing or homelessness. Prog Neuro-Psychopharmacology Biol Psychiatry. 2023;126:110795.","journal-title":"Prog Neuro-Psychopharmacology Biol Psychiatry"},{"key":"7645_CR40","unstructured":"Blackman G, Dobbs RJ, Dobbs S. Extrapyramidal side effects. MAUDSLEY Guidel. 2021;479."},{"issue":"S1","key":"7645_CR41","doi-asserted-by":"publisher","first-page":"S1082","DOI":"10.1192\/j.eurpsy.2023.2298","volume":"66","author":"R Stryjer","year":"2023","unstructured":"Stryjer R, Shelef A. Akathisia rate among psychiatric patients treated with clozapine compared to Risperidone. Eur Psychiatry. 2023;66(S1):S1082\u20131082.","journal-title":"Eur Psychiatry"},{"issue":"2","key":"7645_CR42","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/JCP.0b013e318166c4d5","volume":"28","author":"K Gao","year":"2008","unstructured":"Gao K, Kemp DE, Ganocy SJ, Gajwani P, Xia G, Calabrese JR. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol. 2008;28(2):203\u20139.","journal-title":"J Clin Psychopharmacol"},{"key":"7645_CR43","doi-asserted-by":"crossref","unstructured":"Misgana T, Yigzaw N, Asfaw G. Drug-induced movement disorders and its associated factors among patients attending treatment at public hospitals in Eastern Ethiopia. Neuropsychiatr Dis Treat. 2020;1987\u201395.","DOI":"10.2147\/NDT.S261272"},{"key":"7645_CR44","doi-asserted-by":"crossref","unstructured":"Vasconcelos LP, Gandini J, Teixeira AL, Manto M. Movement disorders associated with stimulants and other drugs of abuse. Mov Disord Psychiatry. 2022.","DOI":"10.1093\/med\/9780197574317.003.0009"},{"key":"7645_CR45","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2165\/00023210-199606040-00006","volume":"6","author":"TRE Barnes","year":"1996","unstructured":"Barnes TRE, McPhillips MA. Antipsychotic-induced extrapyramidal symptoms: role of anticholinergic drugs in treatment. CNS Drugs. 1996;6:315\u201330.","journal-title":"CNS Drugs"},{"key":"7645_CR46","unstructured":"Samulski BS. An investigation of the effect of chewing on rhythmic motor tasks. Old Dominion University; 2020."},{"issue":"1","key":"7645_CR47","first-page":"25","volume":"7","author":"A Mehta","year":"2024","unstructured":"Mehta A, Dugani P, Rangaiah P, Javali M, Acharya P, Srinivasa R. Khat consumption as a modifiable risk factor for chewing dystonia. Ann Mov Disord. 2024;7(1):25\u20138.","journal-title":"Ann Mov Disord"},{"key":"7645_CR48","doi-asserted-by":"crossref","unstructured":"Kaggwa MM, Nkola R, Najjuka SM, Bongomin F, Ashaba S, Mamun MA. Extrapyramidal side effects in a patient with alcohol withdrawal symptoms: a reflection of quality of the mental health care system. Risk Manag Healthc Policy. 2021;2789\u201395.","DOI":"10.2147\/RMHP.S314451"},{"key":"7645_CR49","first-page":"100059","volume":"3","author":"L Gharzai","year":"2020","unstructured":"Gharzai L, Harney J, Higgins S, High R, Xu L, Inciarte D, et al. Alarming levels of stigma toward generalized dystonia: A cross-cultural comparison. Clin Park Relat Disord. 2020;3:100059.","journal-title":"Clin Park Relat Disord"},{"key":"7645_CR50","doi-asserted-by":"publisher","first-page":"S397","DOI":"10.1016\/S0924-977X(01)00109-2","volume":"11","author":"JM Kane","year":"2001","unstructured":"Kane JM. Extrapyramidal side effects are unacceptable. Eur Neuropsychopharmacol. 2001;11:S397\u2013403.","journal-title":"Eur Neuropsychopharmacol"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-07645-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-025-07645-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-07645-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:53:43Z","timestamp":1781618023000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12888-025-07645-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7645"],"URL":"https:\/\/doi.org\/10.1186\/s12888-025-07645-y","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"19 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical clearance for the study was obtained from the Institutional Board Research Review Committee of the College of Health Sciences at Aksum University (IRB Number: 28\/11\/2019). Permission letters were also obtained from the respective city administrations. All study participants were 18 years of age or older. Informed consent was obtained from all participants, and the confidentiality of the collected information was strictly maintained. Participants who screened positive for extrapyramidal symptoms (EPS) were referred to appropriate healthcare providers for further evaluation and management. The study was conducted according to the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Each author approved the manuscript\u2019s publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1189"}}